Aditxt, Inc. Payments of Financing Costs
Aditxt, Inc. (ADTX) reported Payments of Financing Costs of $262.16 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2025-03-31
- Aditxt, Inc. payments of financing costs for the quarter ending 2023-12-31 was $0.00.
- Aditxt, Inc. payments of financing costs for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Aditxt, Inc. payments of financing costs for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Aditxt, Inc. payments of financing costs for the quarter ending 2023-03-31 was $262.16K, a 42.34% increase year-over-year.
- Aditxt, Inc. payments of financing costs for fiscal 2023 was $262.16K, a 34.54% decline from fiscal 2022.
- Aditxt, Inc. payments of financing costs for fiscal 2022 was $400.49K, a 33.14% decline from fiscal 2021.
- Aditxt, Inc. payments of financing costs for fiscal 2021 was $598.98K, a 924.33% increase from fiscal 2020.
- Aditxt, Inc. payments of financing costs for fiscal 2020 was $58.48K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $262.16K 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $262.16K 10-Q · filed 2024-11-18 | $98.90K derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | $262.16K 10-Q · filed 2024-08-19 | $98.90K derived: sum of 3 quarters · filed 2024-08-19 | $290.57K derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $262.16K 10-Q · filed 2024-05-20 | $98.90K derived: sum of 2 quarters · filed 2024-05-20 | $290.57K derived: sum of 3 quarters · filed 2024-05-20 | $478.47K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | -$163.26K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $28.41K derived: sum of 2 quarters · filed 2024-04-16 | $216.31K derived: sum of 3 quarters · filed 2024-04-16 | $400.49K 10-K · filed 2024-04-16 |
| 2022-09-30 | $191.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $379.57K derived: sum of 2 quarters · filed 2023-08-14 | $563.75K 10-Q · filed 2022-11-14 | $744.30K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-06-30 | $187.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $372.08K 10-Q · filed 2023-08-14 | $552.62K derived: sum of 3 quarters · filed 2023-08-14 | $729.61K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $184.18K 10-Q · filed 2023-05-15 | $364.73K derived: sum of 2 quarters · filed 2023-05-15 | $541.72K derived: sum of 3 quarters · filed 2023-05-15 | $675.05K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $180.55K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $357.53K derived: sum of 2 quarters · filed 2023-04-17 | $490.87K derived: sum of 3 quarters · filed 2023-04-17 | $598.98K 10-K · filed 2023-04-17 |
| 2021-09-30 | $176.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $310.32K derived: sum of 2 quarters · filed 2022-11-14 | $418.43K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $133.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $241.44K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $108.11K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $58.48K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |